Campylobacter jejuniInfection and Treatment for Guillain–Barré Syndrome

Abstract

Rees et al. (Nov. 23 issue)¹ reported that patients with the Guillain–Barré syndrome and recent infection with Campylobacter jejuni have a more severe residual disability after one year than patients without C. jejuni infection. In later studies they showed that patients with the combination of C. jejuni infection and antibodies against GM1 ganglioside have the worst prognosis.² The effect of treatment was not included in their analyses, however.